百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688177 百奥泰

交易中 05-17 14:47:58

{"stockData":{"symbol":"688177","market":"SH","secType":"STK","nameCN":"百奥泰","latestPrice":30.14,"timestamp":1715928478000,"preClose":29.3,"halted":0,"volume":1278374,"delay":0,"floatShares":413999999,"shares":413999999,"eps":-0.8958,"marketStatus":"交易中","marketStatusCode":2,"change":0.84,"latestTime":"05-17 14:47:58","open":29.48,"high":30.15,"low":29.33,"amount":38119300,"amplitude":0.028,"askPrice":30.14,"askSize":8,"bidPrice":30.11,"bidSize":8,"shortable":0,"etf":0,"ttmEps":-0.8958,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1715929200000},"adr":0,"adjPreClose":29.3,"symbolType":"stock_kcb","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":32.23,"lowLimit":26.37,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":414080000,"pbRate":11.09,"roa":"--","roe":"--","epsLYR":-0.95,"committee":-0.41779,"marketValue":12480000000,"floatMarketCap":12480000000,"peRate":-33.645903,"changeRate":0.0287,"turnoverRate":0.0031,"status":0},"requestUrl":"/m/hq/s/688177/tweets","defaultTab":"tweets","newsList":[{"id":"2436393389","title":"百奥泰（688177）5月16日主力资金净买入228.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2436393389","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2436393389?lang=zh_cn&edition=full","pubTime":"2024-05-17 07:52","pubTimestamp":1715903536,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月16日收盘，百奥泰报收于29.3元，下跌2.01%，换手率0.29%，成交量1.2万手，成交额3526.0万元。近5日资金流向一览见下表：百奥泰融资融券信息显示，融资方面，当日融资买入313.09万元，融资偿还138.29万元，融资净买入174.8万元，连续3日净买入累计716.85万元。百奥泰主营业务：创新药和生物类似药的研发、生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700010862.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435613136","title":"北向资金5月14日净买入百奥泰13.01万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2435613136","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435613136?lang=zh_cn&edition=full","pubTime":"2024-05-16 09:30","pubTimestamp":1715823040,"startTime":"0","endTime":"0","summary":"5月14日, 北向资金增持百奥泰13.01万股，连续3日增持。截止当日收盘，沪股通共持有百奥泰350.53万股，占流通股0.84%。沪股通增持金额前五个股分别为三一重工、国电南瑞、中远海控、海尔智家、亨通光电。百奥泰近5个交易日下跌12.15%，沪股通累计增持42.07万股；近20个交易日下跌7.66%，沪股通累计增持177.38万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516093629876e52c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516093629876e52c6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435202035","title":"百奥泰（688177）5月14日主力资金净卖出102.38万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435202035","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435202035?lang=zh_cn&edition=full","pubTime":"2024-05-15 07:51","pubTimestamp":1715730679,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月14日收盘，百奥泰报收于30.37元，下跌1.72%，换手率0.53%，成交量2.2万手，成交额6770.0万元。近5日资金流向一览见下表：百奥泰融资融券信息显示，融资方面，当日融资买入510.48万元，融资偿还54.47万元，融资净买入456.01万元。百奥泰主营业务：创新药和生物类似药的研发、生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051500010781.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435565509","title":"百奥泰05月14日主力资金流出154万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2435565509","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435565509?lang=zh_cn&edition=full","pubTime":"2024-05-14 15:19","pubTimestamp":1715671181,"startTime":"0","endTime":"0","summary":"05月14日, 百奥泰股价跌1.72%，报收30.37元，成交金额6769万元，换手率0.53%，振幅4.72%，量比0.96。百奥泰今日主力资金净流出154万元，连续5日净流出，上一交易日主力净流出1579万元，今日环比减少90.25%。该股近5个交易日下跌11.15%，主力资金累计净流出2995万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出5162万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405141538478b0652b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405141538478b0652b5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435862582","title":"百奥泰（688177）5月13日主力资金净卖出1582.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435862582","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435862582?lang=zh_cn&edition=full","pubTime":"2024-05-14 07:49","pubTimestamp":1715644185,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月13日收盘，百奥泰报收于30.9元，下跌6.08%，换手率1.02%，成交量4.21万手，成交额1.32亿元。近5日资金流向一览见下表：百奥泰融资融券信息显示，融资方面，当日融资买入417.53万元，融资偿还365.99万元，融资净买入51.54万元。百奥泰主营业务：创新药和生物类似药的研发、生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051400003890.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435454103","title":"5月13日百奥泰跌6.08%，富国医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435454103","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435454103?lang=zh_cn&edition=full","pubTime":"2024-05-13 16:20","pubTimestamp":1715588458,"startTime":"0","endTime":"0","summary":"证券之星消息，5月13日百奥泰跌6.08%，收盘报30.9元，换手率1.02%，成交量4.21万手，成交额1.32亿元。重仓百奥泰的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级4家。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共14家，其中持有数量最多的公募基金为富国医疗保健行业混合A。该公募基金现任基金经理为孙笑悦。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300014744.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435231417","title":"百奥泰(688177)：商业化推广全球稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2435231417","media":"财通证券","top":-1,"share":"https://www.laohu8.com/m/news/2435231417?lang=zh_cn&edition=full","pubTime":"2024-05-13 14:34","pubTimestamp":1715582053,"startTime":"0","endTime":"0","summary":"事件：近日，公司发布2023 年年报及2024 年1 季报。CHMP 建议欧盟委员会批准BAT1806 上市。BAT1806已于2023 年1 月获得中国国家药品监督管理局批准上市，是国内获批的首个托珠单抗生物类似药，也是全球首个托珠单抗生物类似药。2023 年9 月，BAT1806 获美国FDA 批准上市，是第一个由中国本土药企自主研发、生产且获得美国FDA 上市批准的单克隆抗体药物，也是美国FDA 批准的首款托珠单抗生物类似药。同时，托珠单抗注射液和贝伐珠单抗注射液已向EMA 递交上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131434168b00560b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131434168b00560b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435392545","title":"百奥泰跌5.11% 近半年7家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2435392545","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2435392545?lang=zh_cn&edition=full","pubTime":"2024-05-13 11:04","pubTimestamp":1715569499,"startTime":"0","endTime":"0","summary":"05月13日，百奥泰股价大幅下跌，截至11点04分，百奥泰下跌5.11%，报31.22元/股，成交5293万元，换手率0.40%。此外，数据统计显示，近半年内7家券商给予买入建议。资金动向截止发稿，百奥泰获得主力净流出544万元，其中超大单流出376万元，大单流出166万元。北向资金方面，百奥泰05月10日获得北向资金增持10.31万股，截至05月10日，北向资金当前共持有百奥泰324.23万股，市值1.01亿元，持股占流通股比为0.78%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240513110558792741f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240513110558792741f4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434882534","title":"5月10日百奥泰跌5.13%，富国医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2434882534","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434882534?lang=zh_cn&edition=full","pubTime":"2024-05-10 16:16","pubTimestamp":1715329011,"startTime":"0","endTime":"0","summary":"证券之星消息，5月10日百奥泰跌5.13%，收盘报32.9元，换手率0.71%，成交量2.95万手，成交额9813.83万元。重仓百奥泰的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级4家。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共14家，其中持有数量最多的公募基金为富国医疗保健行业混合A。该公募基金现任基金经理为孙笑悦。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000028782.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434409882","title":"百奥泰：BAT1308（PD-1）联合BAT8006（ADC- FRα）治疗晚期实体瘤获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2434409882","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2434409882?lang=zh_cn&edition=full","pubTime":"2024-05-09 18:39","pubTimestamp":1715251140,"startTime":"0","endTime":"0","summary":"证券时报e公司讯，记者从百奥泰(688177)获悉，公司今日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，在研药品BAT1308联合BAT8006治疗晚期实体瘤的临床试验申请获得批准。其中，BAT1308注射液是百奥泰自主研发的人源化抗PD-1单克隆抗体，能够恢复和提高T细胞的免疫杀伤功能，抑制肿瘤生长；BAT8006是百奥泰开发的靶向叶酸受体α（FRα）的抗体药物偶联物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405091840098aec8607&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405091840098aec8607&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434106993","title":"百奥泰(688177.SH)：在研药品BAT1308联合BAT8006治疗晚期实体瘤的临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2434106993","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2434106993?lang=zh_cn&edition=full","pubTime":"2024-05-09 17:24","pubTimestamp":1715246699,"startTime":"0","endTime":"0","summary":"格隆汇5月9日丨百奥泰(688177.SH)公布，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研药品BAT1308联合BAT8006治疗晚期实体瘤的临床试验申请获得批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050917250387e431cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050917250387e431cb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434696890","title":"百奥泰(688177.SH)：BAT1308联合BAT8006治疗晚期实体瘤临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2434696890","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434696890?lang=zh_cn&edition=full","pubTime":"2024-05-09 17:24","pubTimestamp":1715246671,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研药品BAT1308联合BAT8006治疗晚期实体瘤的临床试验申请获得批准。BAT8006是百奥泰开发的靶向叶酸受体α(FRα)的抗体药物偶联物拟开发用于实体肿瘤治疗。BAT8006由重组人源化抗FRα抗体与毒性小分子拓扑异构酶I抑制剂，通过公司自主研发的可剪切连接子连接而成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119318.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434057656","title":"百奥泰05月09日遭主力抛售544万元 环比增加854.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434057656","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2434057656?lang=zh_cn&edition=full","pubTime":"2024-05-09 15:18","pubTimestamp":1715239138,"startTime":"0","endTime":"0","summary":"05月09日, 百奥泰股价涨1.91%，报收34.68元，成交金额3400万元，换手率0.24%，振幅2.82%，量比0.60。百奥泰今日主力资金净流出544万元，上一交易日主力净流出57万元，今日环比增加854.39%。|05月09日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|N欧莱|29.15%|#|金杨股份|8.63%|#|北方长龙|6.21%|#|蓝海华腾|4.77%|#|美农生物|4.28%|#|惠柏新材|3.47%|#|积成电子|3.46%|#|达嘉维康|3.45%|#|山东矿机|3.44%|#|合纵科技|2.96%|百奥泰所在的生物制品行业，今日主力净流入2601万元，行业排名69/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050915340387e3978e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050915340387e3978e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433791712","title":"百奥泰(688177.SH)：乌司奴单抗注射液上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2433791712","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433791712?lang=zh_cn&edition=full","pubTime":"2024-05-08 17:01","pubTimestamp":1715158884,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰(688177.SH)公告，公司近日收到国家药品监督管理局核准签发的关于公司在研药品乌司奴单抗注射液(简称“BAT2206”)药品上市许可申请的《受理通知书》。公告称，BAT2206是百奥泰根据国家药监局、美国FDA、欧盟EMA生物类似药相关指导原则开发的乌司奴单抗注射液，乌司奴单抗是一款靶向白细胞介素IL-12和IL-23共有的p40亚基的全人源单克隆抗体。IL-12和IL-23是天然产生的细胞因子，能够参与炎症和免疫应答过程，可以与p40亚基以高亲和力特异性地结合，阻断其与细胞表面受体结合，从而破坏IL-12和IL-23介导的信号传导和细胞因子的效应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1118771.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433765322","title":"北向资金5月7日净买入百奥泰22.53万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2433765322","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433765322?lang=zh_cn&edition=full","pubTime":"2024-05-08 09:30","pubTimestamp":1715131839,"startTime":"0","endTime":"0","summary":"5月7日, 北向资金增持百奥泰22.53万股，连续3日增持。截止当日收盘，沪股通共持有百奥泰308.46万股，占流通股0.74%。沪股通增持金额前五个股分别为贵州茅台、海尔智家、中国平安、交通银行、恒瑞医药。百奥泰近5个交易日上涨9.99%，沪股通累计增持58.24万股；近20个交易日下跌1.45%，沪股通累计增持151.95万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405080935088ae6cf59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405080935088ae6cf59&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433249718","title":"百奥泰05月07日主力资金流入277万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2433249718","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433249718?lang=zh_cn&edition=full","pubTime":"2024-05-07 15:18","pubTimestamp":1715066320,"startTime":"0","endTime":"0","summary":"05月07日, 百奥泰股价涨1.14%，报收34.57元，成交金额7094万元，换手率0.49%，振幅4.10%，量比1.18。百奥泰今日主力资金净流入277万元，连续3日净流入，上一交易日主力净流入250万元，今日环比增加10.80%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为70.00%，平均涨幅为3.84%。该股近5个交易日上涨9.99%，主力资金累计净流入461万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出5510万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405071530008ae4160e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405071530008ae4160e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431280034","title":"百奥泰大跌5.05% 近半年7家券商买入建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2431280034","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2431280034?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:35","pubTimestamp":1714440944,"startTime":"0","endTime":"0","summary":"04月30日，百奥泰股价大幅下跌，截至09点35分，百奥泰下跌5.05%，报31.61元/股，成交1024万元，换手率0.08%，振幅4.45%。此外，数据统计显示，近半年内7家券商给予买入建议。资金动向截止发稿，百奥泰获得主力净流出121万元，其中超大单流出4万元，大单流出115万元。北向资金方面，百奥泰04月29日获得北向资金减持10.77万股，截至04月29日，北向资金当前共持有百奥泰253.36万股，市值8008万元，持股占流通股比为0.61%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300939087a578658&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300939087a578658&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431381224","title":"图解百奥泰一季报：第一季度单季净利润同比增16.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431381224","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431381224?lang=zh_cn&edition=full","pubTime":"2024-04-30 01:59","pubTimestamp":1714413592,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰2024年一季报显示，公司主营收入1.62亿元，同比上升4.3%；归母净利润-1.19亿元，同比上升16.57%；扣非净利润-1.23亿元，同比上升27.77%；负债率51.59%，财务费用386.19万元，毛利率69.91%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000002693.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431837750","title":"百奥泰(688177.SH)发布一季度业绩，净亏损1.19亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431837750","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431837750?lang=zh_cn&edition=full","pubTime":"2024-04-29 19:27","pubTimestamp":1714390031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰(688177.SH)发布2024年一季度报告，报告期内公司实现营业收入1.62亿元，同比增加4.3%;归属于上市公司股东的净亏损1.19亿元;归属于上市公司股东的扣除非经常性损益的净亏损1.23亿元;基本每股亏损0.29元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114743.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430241999","title":"百奥泰：托珠单抗注射液获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2430241999","media":"国际金融报","top":-1,"share":"https://www.laohu8.com/m/news/2430241999?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:13","pubTimestamp":1714119204,"startTime":"0","endTime":"0","summary":"百奥泰公告，TOFIDENCE(托珠单抗注射液)获欧洲药品管理局人用药品委员会积极意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261613577a5607ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261613577a5607ab&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-02-21","address":"广东省广州市黄埔区高新技术产业开发区科学城开源大道11号A6栋第五层","stockEarnings":[{"period":"1week","weight":-0.1551},{"period":"1month","weight":0.031},{"period":"3month","weight":-0.0669},{"period":"6month","weight":-0.232},{"period":"1year","weight":-0.0327},{"period":"ytd","weight":-0.2895}],"companyName":"百奥泰生物制药股份有限公司","boardCode":"AI0027","perCapita":"56322股","boardName":"医药制造业","registeredCapital":"41408万元","compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":0.0384},{"period":"3month","weight":0.0895},{"period":"6month","weight":0.0223},{"period":"1year","weight":-0.0493},{"period":"ytd","weight":0.0496}],"survey":"　　百奥泰生物制药股份有限公司的主营业务是药物的研发、生产和销售。公司的主要产品是创新药和生物类似药，用于治疗肿瘤、自身免疫性疾病、心血管疾病以及其它危及人类生命或健康的重大疾病。","serverTime":1715928498200,"listedPrice":32.76,"stockholders":"7352人(较上一季度减少0.97%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥泰,688177,百奥泰股票,百奥泰股票老虎,百奥泰股票老虎国际,百奥泰行情,百奥泰股票行情,百奥泰股价,百奥泰股市,百奥泰股票价格,百奥泰股票交易,百奥泰股票购买,百奥泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}